Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT06909708Recruiting
Comparing two liver cancer treatments for unresectable tumors
This trial compares two treatments for liver cancer that cannot be removed by surgery: SIRT (a type of internal radiation) and cTACE (a type of targeted chemo). It aims to see which is more effective for patients with limited tumor spread and good liver function.
Nanjing, JiangsuAges 18 years+ - NCT03812874RecruitingPhase 1/Phase 2
Drug after chemo-embolization for liver cancer that can’t be removed
This Phase 1/2 study tests PTX-9908 (a study drug) to see if it’s safe and effective when given after TACE, a liver-directed treatment. It may help people with liver cancer that can’t be surgically removed and who have recovered enough from their recent TACE.
New Taipei City, TaiwanAges 20 years+ - NCT05276037Recruiting
PET/CT scan to guide liver transplant decisions in liver cancer
This trial studies how a whole-body PET/CT scan using a “tracer” called 18F-FDG can help decide which people with liver cancer (HCC) may benefit from a liver transplant. It may help the transplant team better sort out who is likely to do well after transplant.
AntwerpAges 18–80 - NCT05971108Recruiting
Check a blood test system to catch liver cancer early
This study will test a real-world blood testing system (Elecsys GAAD) to improve surveillance and earlier detection of liver cancer in people who already have liver scarring (cirrhosis). If it works well, it could help find liver cancer sooner and potentially improve outcomes.
Manchester, Greater ManchesterAges 18 years+ - NCT06061276Recruiting
Combined therapy for large liver cancer with limited spread
This trial tests a combination of treatments—bland transarterial embolization (bTAE), hepatic artery infusion chemotherapy (HAIC), and systemic therapy—for people with large liver cancers that have limited spread. It might be an option if you have a big tumor and your liver is still working well.
Guanzhou, GuangdongAges 18–75 - NCT06349317RecruitingPhase 2
Radiation, immunotherapy, and targeted therapy before surgery for liver cancer with portal vein tumor thrombus
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Fuzhou, FujianAges 18–75 - NCT06418659RecruitingEarly Phase 1
CD-801 for advanced liver cancer
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06492395RecruitingPhase 3
Three treatments for large liver cancer with portal vein spread
This trial tests adding a second liver-directed treatment (hepatic artery infusion) to the usual combination of targeted therapy (lenvatinib) and chemoembolization (DEB-TACE) for people with large liver cancer that has spread into the portal vein, to see if the triple therapy works better.
Guangzhou, GuangdongAges 18–75 - NCT07148310Recruiting
A blood and tissue test for liver cancer
This study is looking at a new way to find liver cancer by testing blood and tissue samples. It compares people with liver cancer to people with liver scarring (cirrhosis) but no cancer.
MendozaAges 18–75 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT06812039RecruitingPhase 2
Perioperative treatment for high-risk liver cancer using HAIC, donafenib, and sintilimab
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
Fuzhou, FujianAges 18–75 - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT06172205RecruitingPhase 3
Two ways to give chemo plus immunotherapy for advanced liver cancer
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
Guangzhou, GuangdongAges 18–75 - NCT07059494RecruitingPhase 4
Combination therapy for liver cancer before transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
New York, New YorkAges 18 years+ - NCT05377034RecruitingPhase 2
Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
BeijingAges 21–99 - NCT05984511Recruiting
Combined treatment for liver cancer with portal vein tumor thrombus
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–75 - NCT06537193Recruiting
Shorter MRI vs CT scan to check for liver cancer return
This trial compares a shorter MRI using a special dye to a CT scan for detecting liver cancer recurrence in people who have been cancer-free for at least two years after surgery or local treatment.
Seoul, Songpa-gu , 88, Olympic-ro 43-gilAges 20 years+ - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06602011Recruiting
Triple therapy for advanced liver cancer with bile duct invasion
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
Fuzhou, FujianAges 18–75 - NCT06669377Recruiting
Combination therapy for liver cancer with main portal vein tumor clot
This trial tests a combination of treatments for liver cancer that has spread to the main portal vein. It uses a special stent, radiation seeds, and targeted therapies to shrink the tumor and improve blood flow. This may help patients who haven't had certain prior treatments.
Nanjing, JiangsuAges 18 years+ - NCT06707233RecruitingPhase 2
Y-90 radioembolization for large liver cancer (over 7 cm)
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07235410Recruiting
Body composition study for liver cancer patients having TACE
This trial uses deep learning to analyze body composition from scans in people with hepatocellular carcinoma (HCC) who are undergoing TACE (a treatment that blocks blood flow to the tumor). It aims to predict outcomes better and may help doctors tailor care.
Wuhan, HubeiAges 18 years+
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 484 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.